GlaucomaNCT02959242
Dresden Glaucoma and Treatment Study (DGTS)
An observational study of Glaucoma and Glaucoma, Open-Angle, run by Technische Universität Dresden at 1 site in Germany.
Trial summary
To assure the quality of follow-up and treatment, data of glaucoma patients are stored and evaluated after anonymisation. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Glaucoma, Glaucoma, Open-Angle, Glaucoma, Angle-Closure
- How many people
- 10,000 participants
- Where
- 1 siteGermany
- Study dates
- Jan 2006to Dec 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Glaucoma patients attending a tertiary University Hospital glaucoma Service.
Who may be able to join
- manifest glaucoma, ocular Hypertension, glaucoma suspect
Who cannot join
- under 18 years of age, corneal diseases
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Eye Hospital, Medical Faculty, Technical University Dresden
Dresden, Saxony, 01307
Karin R Pillunat, MD, +49 351 458 ext. 3274, karin.pillunat@uniklinikum-dresden.de
Lutz E Pillunat, MD, PhD, +49 351 458 ext. 3381, lutze.pillunat@uniklinikum-dresden.de
About this study
Official title: Dresden Glaucoma and Treatment Study: Analysis to Assure the Quality of Follow-up and Therapy of Glaucoma Patients in a Tertiary University Hospital Glaucoma Service.
To assure the quality of follow-up and treatment, data of glaucoma patients are stored and evaluated after anonymisation.
Read the detailed description
The aim of the study is to evaluate the quality of follow-up and treatment by means of consecutive data collection and anonymised analysis of all glaucoma patients of a tertiary university hospital glaucoma service.
Parameters being analyzed are:
Age, sex, refraction, family history, known duration of glaucoma, highest intraocular pressure before treatment, systemic and topical medication, previous ocular surgery.
24h Goldmann-applanation tonometry, biomicroscopy, gonioscopy, Heidelberg Retinal Tomograph (HRT), glaucoma diagnosis with Scanning-Laser-Polarimetry (GDx), optical coherence tomography (OCT), Pentacam, Ocular Response Analyzer (ORA), Corvis ST (Corneal Visualization with the Scheimpflug Technology), perimetry
- Keywords
- Follow-up intervals, Treatment Efficiency, Laser Therapy, Glaucoma Surgery, Minimal Invasive Glaucoma Surgery (MIGS)
- Medical subject headings
- Glaucoma, Glaucoma, Open-Angle, Glaucoma, Angle-Closure, Low Tension Glaucoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Follow-up intervals
To find the best follow-up intervals for glaucoma patients.
Measured: 20 years
Secondary outcomes (3)
Assessment of treatment quality
What is the best treatment option for the individual patient?
Measured: 20 years
Assessment of intraocular pressure-lowering efficacy and number of participants with treatment-related adverse events as assessed by CTCAE v4.0 of glaucoma laser therapy
Diurnal intraocular pressure, best corrected visual acuity, visual fields
Measured: 20 years
Assessment of intraocular pressure-lowering efficacy and number of participants with treatment-related adverse events as assessed by CTCAE v4.0 of glaucoma laser therapy of glaucoma surgery
Diurnal intraocular pressure, best corrected visual acuity, visual fields
Measured: 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2016 (estimated)
- Study startJan 2006
- Primary completionDec 2032 (estimated)
- Study completionDec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Technische Universität Dresden
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Karin Pillunat, Technische Universität Dresden
- Investigators
- Lutz E Pillunat, MD, PhD, Study director, Medical faculty of the Technical University of Dresden, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02959242
- Sponsor's protocol ID
- DGTS
- Status last verified
- Sep 2026
- First submitted
- 7 Nov 2016
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: Individual participant data are only shared between researchers of our Institute.
Publications
Pillunat KR, Herber R, Jamke M, Jasper CS, Haase MA, Manseck AS, Pillunat LE. Early Results of Preserflo MicroShunt for Primary Open Angle Glaucoma in White Patients. J Glaucoma. 2025 Feb 1;34(2):103-113. doi: 10.1097/IJG.0000000000002509. Epub 2024 Oct 11.
PubMed 39401481Jamke M, Herber R, Haase MA, Jasper CS, Pillunat LE, Pillunat KR. PRESERFLO MicroShunt versus trabeculectomy: 1-year results on efficacy and safety. Graefes Arch Clin Exp Ophthalmol. 2023 Oct;261(10):2901-2915. doi: 10.1007/s00417-023-06075-4. Epub 2023 May 3.
PubMed 37133501Pillunat KR, Kocket GA, Herber R, Jasper CS, Lenk J, Pillunat LE. Efficacy of selective laser trabeculoplasty on lowering intraocular pressure fluctuations and nocturnal peak intraocular pressure in treated primary open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):1979-1985. doi: 10.1007/s00417-022-05897-y. Epub 2022 Nov 23.
PubMed 36418515
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dresden Glaucoma and Treatment Study: Analysis to Assure the Quality of Follow-up and Therapy of Glaucoma Patients in a Tertiary University Hospital Glaucoma Service.
- ClinicalTrials.gov ID
- NCT02959242
- Acronym / sponsor ID
- DGTS
- Keywords
- Follow-up intervals, Treatment Efficiency, Laser Therapy, Glaucoma Surgery, Minimal Invasive Glaucoma Surgery (MIGS)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Technische Universität DresdenUniversity, hospital or other
- Study start
- Jan 2006 (actual)
- Primary completion
- Dec 2032 (estimated)
- Study completion
- Dec 2032 (estimated)
- First posted
- 9 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assure the quality of follow-up and treatment, data of glaucoma patients are stored and evaluated after anonymisation.
Detailed description
The aim of the study is to evaluate the quality of follow-up and treatment by means of consecutive data collection and anonymised analysis of all glaucoma patients of a tertiary university hospital glaucoma service.
Parameters being analyzed are:
Age, sex, refraction, family history, known duration of glaucoma, highest intraocular pressure before treatment, systemic and topical medication, previous ocular surgery.
24h Goldmann-applanation tonometry, biomicroscopy, gonioscopy, Heidelberg Retinal Tomograph (HRT), glaucoma diagnosis with Scanning-Laser-Polarimetry (GDx), optical coherence tomography (OCT), Pentacam, Ocular Response Analyzer (ORA), Corvis ST (Corneal Visualization with the Scheimpflug Technology), perimetry
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Glaucoma patients attending a tertiary University Hospital glaucoma Service.
Key inclusion criteria (1 listed)
- manifest glaucoma, ocular Hypertension, glaucoma suspect
Key exclusion criteria (1 listed)
- under 18 years of age, corneal diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Follow-up intervals
Time frame: 20 years
To find the best follow-up intervals for glaucoma patients.
3 secondary outcomes
Assessment of treatment quality
Time frame: 20 years
Assessment of intraocular pressure-lowering efficacy and number of participants with treatment-related adverse events as assessed by CTCAE v4.0 of glaucoma laser therapy
Time frame: 20 years
Assessment of intraocular pressure-lowering efficacy and number of participants with treatment-related adverse events as assessed by CTCAE v4.0 of glaucoma laser therapy of glaucoma surgery
Time frame: 20 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Derived from this study: PubMed 39401481Pillunat KR, Herber R, Jamke M, Jasper CS, Haase MA, Manseck AS, Pillunat LE. Early Results of Preserflo MicroShunt for Primary Open Angle Glaucoma in White Patients. J Glaucoma. 2025 Feb 1;34(2):103-113. doi: 10.1097/IJG.0000000000002509. Epub 2024 Oct 11.
- Derived from this study: PubMed 37133501Jamke M, Herber R, Haase MA, Jasper CS, Pillunat LE, Pillunat KR. PRESERFLO MicroShunt versus trabeculectomy: 1-year results on efficacy and safety. Graefes Arch Clin Exp Ophthalmol. 2023 Oct;261(10):2901-2915. doi: 10.1007/s00417-023-06075-4. Epub 2023 May 3.
- Derived from this study: PubMed 36418515Pillunat KR, Kocket GA, Herber R, Jasper CS, Lenk J, Pillunat LE. Efficacy of selective laser trabeculoplasty on lowering intraocular pressure fluctuations and nocturnal peak intraocular pressure in treated primary open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):1979-1985. doi: 10.1007/s00417-022-05897-y. Epub 2022 Nov 23.
- Individual participant dataSharing planned: No. Individual participant data are only shared between researchers of our Institute.
Related trials for Glaucoma
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
Active, not recruitingObservational study
Impact of Glaucoma and Visual Field Loss on Life Space
Primary Open-angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Recruiting
Timing of Glaucoma Drainage Device With Boston Keratoprosthesis
Corneal Transplantation, Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lutz E Pillunat, MD, PhD study director
Medical faculty of the Technical University of Dresden, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma and Glaucoma, Open-Angle, run by Technische Universität Dresden at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Karin R Pillunat, MD (+49 351 458 3274, karin.pillunat@uniklinikum-dresden.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Follow-up intervals (time frame: 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02959242, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026; AzTrials last refreshed its copy on 29 Oct 2026.